Cancer: Overview of Types, Symptoms, & Treatments: Stomach Cancer

n the past, esophageal cancer was linked to heavy smoking and drinking, but recent research points to a new culprit: acid reflux. This program examines the causes, diagnosis, and treatment of esophageal cancer. Case studies and commentary from leading medical experts in the field elucidate the causal chain between age; obesity; gastroesophageal reflux disease, or GERD; and Barrett’s esophagus, a precursor to esophageal cancer. Gastroenterologists also discuss how long-term use of over-the-counter and prescription antacids can mask important warning signs of this disease.

In this episode, Dr. Alice Roberts uses dissection, drawing, and some unusual tests to reveal where the stomach and intestines are, how big they are, and how best to look after them. Dr. Roberts is joined by Lesley Love, a 40-year-old estate agent whose diet is based almost entirely on chocolate and cheese. The doctor embarks on a mission to impress upon her the need for more fruit and vegetables. She reveals that it is normal to defecate as seldom as once every three days or as often as three times a day. It is important to be aware of one’s bowel habits and take notice of any changes, as these can be signs of bowel cancer.

Learning about stomach (gastric) cancer can be intimidating. Mohamad (Bassam) Sonbol, M.D., an oncologist at Mayo Clinic, walks you through the facts, the questions, and the answers to help you better understand this condition. For more reading visit: https://mayocl.in/3IW8Gm7. When it comes to your health, Mayo Clinic believes credible and clear information is paramount. There’s a lot to learn about stomach cancer. We’re here to help.

The present study aimed to investigate the effects of S-l combined with palliative care (PC) on the immune function and quality of life (QOL) of patients with advanced stomach cancer (ASC). In this prospective study, 168 patients with ASC admitted to our hospital from September 2016 to March 2018 were enrolled as research objects. Seventy-seven cases were treated with S-l alone (single drug group, SDG), while another 91 cases were treated with S-l combined with PC (combined drug group, CDG). The effects of the two therapeutic methods on the efficacy [overall response rate (ORR)], 1-year overall survival rate (OSR), safety, negative emotions, nutritional indices, QOL, and immune function indices of patients were analyzed. After treatment, ORR, OSR, levels of nutritional indices [albumin (ALB), prealbumin (PA), and transferrin (TF)], and QOL improvement rate in the CDG were significantly higher than those in the SDG (P<0.05). After treatment, compared with those in the SDG, patients in the CDG had a lower Self-Rating Anxiety Scale (SAS) score, Self-Rating Depression Scale (SDS) score, and number of adverse reactions (P<0.05), and significantly improved immune function indices (CD4 (+), CD8 (+), and CD4 (+) /CD8 (+) ) (P<0.05). S-l combined with PC treatment was superior to S-l treatment alone in patients with ASC. The patients treated with the combination exhibited improved efficacy (a higher ORR), higher QOL, and improved immune function, and thus this treatment can be clinically popularized.

Stomach cancer was a leading cause of cancer-related deaths early in the 20th century and has steadily declined over the last century in the United States. Although incidence and death rates are now low, stomach cancer remains an important cause of morbidity and mortality in black, Asian and Pacific Islander, and American Indian/Alaska Native populations.